Targeting vesicular monoamine transporter Type 2 for noninvasive PET-based β-cell mass measurements

Authors: Maffei, Antonella; Harris, Paul E

Source: Expert Review of Endocrinology and Metabolism, Volume 2, Number 1, January 2007 , pp. 35-46(12)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

The common pathology in both Types 1 and 2 diabetes is insufficient β-cell mass to meet the metabolic needs of insulin production. The rising worldwide incidence of diabetes, combined with the lack of reliable endpoints of the body's true capacity to produce insulin, constitute a serious dilemma facing healthcare professionals and the pharmaceutical industry. Recent advances in imaging science and molecular imaging chemistry, as well as a broader understanding of basic islet biology, now allow the collection of quantitative information about β cells deep within the pancreas. The ability to noninvasively measure the mass of insulin-producing cells will most likely be of value towards characterizing new drugs and refining the diagnosis and treatment of this burdensome disease.

Keywords: β cell; diabetes; imaging; pancreas; PET

Document Type: Research article

DOI: http://dx.doi.org/10.1586/17446651.2.1.35

Publication date: 2007-01-01

More about this publication?

Expert Review of Endocrinology & Metabolism provides extensive coverage of state-of-the-art research and clinical advancements in the field of endocrine control and metabolism, with a focus on screening, prevention, diagnostics, existing and novel therapeutics, as well as related molecular genetics, pathophysiology and epidemiology
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites